Physician profile
Rodolfo Nellas
NPI 1609868611
$2,095.73
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,096.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $510.77 | 2019 | |
| Neurocrine Biosciences, INC. | $377.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $282.85 | 2019 | |
| Indivior INC. | $209.51 | 2019 | |
| Sunovion Pharmaceuticals INC. | $209.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $170.22 | 2019 | |
| Bausch Health US, LLC | $74.33 | 2019 | |
| Mdd US Operations, LLC | $45.65 | 2019 | |
| Allergan, INC. | $41.66 | 2019 | |
| Orexo US, INC. | $41.66 | 2019 | |
| Neos Therapeutics, LP | $34.15 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.00 | 2019 | |
| Shire North American Group INC | $22.04 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.05 | 2019 | |
| Ironshore Pharmaceuticals INC. | $20.35 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Nellas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.